Operating Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Summary of segmental information
Contract/Grant Revenue	$ 2,630,986	$ 816,286
Income/(Loss) from Operations	(1,905,705)	(1,558,267)
Amortization and Depreciation Expense	22,607	59,926
Interest Income/(Expense)	(3,885)	561
Share-Based Compensation	136,411	142,025
Identifiable Assets	5,591,020		$ 7,387,122
Vaccines/BioDefense [Member]
Summary of segmental information
Contract/Grant Revenue	2,630,986	802,314
Income/(Loss) from Operations	317,991	84,681
Amortization and Depreciation Expense	10,019	9,786
Share-Based Compensation	28,006	24,592
Identifiable Assets	$ 1,150,768		2,123,676
BioTherapeutics [Member]
Summary of segmental information
Contract/Grant Revenue		13,972
Income/(Loss) from Operations	$ (1,245,585)	(764,876)
Amortization and Depreciation Expense	10,433	48,374
Share-Based Compensation	34,832	29,256
Identifiable Assets	70,274		76,183
Corporate [Member]
Summary of segmental information
Income/(Loss) from Operations	(978,111)	(878,072)
Amortization and Depreciation Expense	2,155	1,766
Interest Income/(Expense)	(3,885)	561
Share-Based Compensation	73,573	$ 88,177
Identifiable Assets	$ 4,369,978		$ 5,187,263